# Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

> **NCT02159989** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 83 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Fibrolamellar Carcinoma
- Metastatic Malignant Solid Neoplasm
- Ovarian Carcinoma
- Pancreatic Neuroendocrine Tumor
- Recurrent Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** Sapanisertib
- **BIOLOGICAL:** Ziv-Aflibercept

## Key facts

- **NCT ID:** NCT02159989
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-18
- **Primary completion:** 2021-06-29
- **Final completion:** 2024-01-29
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02159989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02159989, "Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02159989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*